Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.
A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.
The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.
The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.
The firm's shares fell 4% in recent trading on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。